CY, MTX, and ARA-C, the three chemotherapeutics that were partially effective in ameliorating GVHD, all were distinct in restraining alloreactive CD4+Foxp3- T-cell differentiation at day +7, with less effector/effector memory and more naïve/central memory phenotypes (Figure 7A). Here, FOXP3 is linked to graft versus host disease.